已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effectiveness of a New Tablet Formulation for Twice Daily Balsalazide Disodium in Males versus Females with Mildly to Moderately Active Ulcerative Colitis

作者
Ellen Scherl,Salam F. Zakko,Andrew C. Barrett,Enoch B. Bortey,Craig A. Paterson,William P. Forbes
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:108: S546-S546
标识
DOI:10.14309/00000434-201310001-01811
摘要

Purpose: A new formulation of balsalazide disodium tablets (BDT) was developed to allow less frequent dosing for enhanced compliance in the treatment of ulcerative colitis (UC). This study reports on a subgroup analysis comparing the efficacy of BDT in males vs. females with active UC. Methods: Adult subjects with mildly to moderately active UC and a baseline Modified Mayo Disease Activity Index (MMDAI) score between 6 and 10, inclusive, with a subscale rating of ≥ 2 for rectal bleeding and mucosal appearance were randomized 2:1 to receive 3.3 g of BDT (dosed as three 1.1 g tablets twice daily) or PBO tablets for 8 weeks. The primary endpoint was the proportion of patients achieving clinical improvement (≥ 3 point improvement in MMDAI) and improvement in rectal bleeding (≥ 1 point improvement) at 8 weeks. Results: The intent-to-treat population (n=249, mean age: 44 years, 84% white, 49% male) had a median baseline MMDAI score of 8 and a median baseline rectal bleeding sub-score of 2. In males, the proportion of primary endpoint responders was greater in the BDT group (56.8%) than the PBO group (20.0%, p = 0.0001) (Figure). Similar results were obtained for pre-specified secondary endpoints of clinical remission (p = 0.004 vs. PBO) and mucosal healing (p = 0.0007 vs. PBO) (Figure). Although BDT produced a similar response in females, this effect is not statistically significant for the primary endpoint (BDT: 54.1% vs. PBO: 58.1%, p=0.67) or secondary endpoints at week 8 (Figure). However, when more stringent definitions of “clinical remission” (endoscopy score of 0 or 1 and rectal bleeding score of 0 at end of treatment) were applied, the effect of BDT was more consistent across gender groups. Adverse events and serious adverse events in the BDT group were similar to placebo, and not different between genders.Figure: Primary and Secondary Endpoints at 8 Weeks.Conclusion: For the treatment of mild-to-moderate active UC, BDT showed statistically significant efficacy in males, but not in females. The definition of clinical remission in the study may have contributed to the high PBO response in females. The potential influence of gender should be explored in studies of inflammatory bowel disease. Disclosure - Ellen J Scherl: received grants from, served as a consultant for, and is on the speakers' bureau for Salix Pharmaceuticals, Inc.; received grants from and served as a consultant for Abbott, Centocor, Janssen Research and Development, PDL BioPharma, Prometheus Laboratories, and UCB; received grants from Elan, Millennium Pharmaceuticals, and Osiris Therapeutics; and served as a consultant for AstraZeneca, Axcan Pharma, Berlex Inc., Cerimon Pharmaceuticals, Hospira Inc., NPS Pharmaceuticals, Inc., Optimer Pharmaceuticals, Questcor Pharmaceuticals, Shire, Sigma Tau Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc., and TAP Pharmaceuticals. Salam Zakko: has serves as principal investigator on a variety of Salix research protocols, is a recipient of unrestricted grants from Salix, lectures for Salix, and holds stock in Salix. Andrew C. Barrett: employee of and holds stock in Salix Pharmaceuticals, Inc. Enoch Bortey: employee of and holds stock in Salix Pharmaceuticals, Inc. Craig Paterson: employee of and holds stock in Salix Pharmaceuticals, Inc. William P. Forbes: officer and employee of and holds stock in Salix Pharmaceuticals, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyyzyy完成签到 ,获得积分10
1秒前
橘络完成签到,获得积分10
1秒前
误会完成签到 ,获得积分10
2秒前
wuwu发布了新的文献求助10
2秒前
wzrm完成签到,获得积分10
3秒前
张硕完成签到 ,获得积分10
5秒前
LiuSD完成签到,获得积分10
6秒前
6秒前
han完成签到,获得积分10
8秒前
Maestro_S的应助被DW采纳,获得10
9秒前
Treayoung完成签到 ,获得积分10
10秒前
julien完成签到,获得积分10
11秒前
matrixu完成签到,获得积分10
12秒前
12秒前
13秒前
阿格完成签到 ,获得积分10
13秒前
u725694发布了新的文献求助60
13秒前
李爱国的应助被wzrm采纳,获得10
15秒前
16秒前
超帅的香露完成签到,获得积分10
19秒前
格洛完成签到 ,获得积分10
19秒前
民工完成签到,获得积分10
21秒前
3921337477的应助被u558069采纳,获得60
21秒前
在水一方的应助被qq采纳,获得10
23秒前
华仔的应助被qq采纳,获得10
23秒前
大兔米菲发布了新的文献求助10
23秒前
菲菲菲非常美丽的毛毛完成签到,获得积分10
24秒前
光亮靳完成签到,获得积分10
25秒前
26秒前
Qi完成签到 ,获得积分10
27秒前
alex的应助被浪迹采纳,获得30
27秒前
zzw完成签到,获得积分10
28秒前
yy完成签到 ,获得积分10
28秒前
29秒前
wuwu完成签到,获得积分10
29秒前
Kkicesong发布了新的文献求助10
30秒前
31秒前
32秒前
u558069发布了新的文献求助60
35秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184867
求助须知:如何正确求助?哪些是违规求助? 9573803
关于积分的说明 21833148
捐赠科研通 7782177
什么是DOI,文献DOI怎么找? 3434414
关于科研通互助平台的介绍 2558563
邀请新用户注册赠送积分活动 2481067